Search

Your search keyword '"Schönland, Stefan"' showing total 937 results

Search Constraints

Start Over You searched for: Author "Schönland, Stefan" Remove constraint Author: "Schönland, Stefan"
937 results on '"Schönland, Stefan"'

Search Results

2. Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

3. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

4. Systemic Light Chain Amyloidosis

5. High-throughput electron tomography identifies centriole over-elongation as an early event in plasma cell disorders

6. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

8. An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

11. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

12. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

13. Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT

15. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial

16. Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial

17. Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens

18. Proposed hematologic progression criterion in patients with AL amyloidosis.

24. Biomarker-based renal response and progression criteria in AA amyloidosis: results from the testing cohort of the Pavia-Heidelberg study

25. Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

26. Amyloidose

27. Allogeneic hematopoietic stem cell transplantation for adult HLH: a retrospective study by the chronic malignancies and inborn errors working parties of EBMT

28. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia

29. Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network

33. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

35. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

38. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

39. Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma.

40. Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT

41. Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

43. Pre-transplant EASIX and sepsis after allogeneic stem cell transplantation

44. Machine Learning Can Distinguish Hypertrophic Cardiomyopathy, Cardiac Light Chain and Transthyretin Amyloidosis Using Cardiac Magnetic Resonance Imaging Data and Standard Clinical Information

46. Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients over 60 years of age: a prospective phase II study

47. Search for AL amyloidosis risk factors using Mendelian randomization

Catalog

Books, media, physical & digital resources